{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"90"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"373"},{"groupId":"OG001","value":"184"}],"units":"Participants"}],"groups":[{"description":"Participants with HER2-low, unresectable, and/or metastatic breast cancer who were previously treated with chemotherapy were randomized to receive an intravenous infusion of DS8201a (initial dose of 5.4 mg/kg) over approximately 90 minutes. If there was no infusion-related reaction (IRR), T-DXd doses after the initial dose of 5.4 mg/kg were infused over a minimum of 30 minutes.","id":"OG000","title":"Trastuzumab Deruxtecan (T-DXd)"},{"description":"Participants with HER2-low, unresectable, and/or metastatic breast cancer who were previously treated with chemotherapy and randomized to a physician's choice (capecitabine, eribulin, gemcitabine, paclitaxel, and nab-paclitaxel) in which the dose, regimen, administration, and dose modification followed the label approved in the country of drug administration or the National Comprehensive Cancer Network guidelines.","id":"OG001","title":"Physician's Choice"}],"paramType":"NUMBER","populationDescription":"Overall survival events (deaths) were analyzed in the Full Analysis Set (defined as all randomized participants).","reportingStatus":"POSTED","timeFrame":"From the date of randomization up to the date of death due to any cause, up to approximately 3 years","title":"Number of Overall Survival Events (Deaths)","type":"SECONDARY","unitOfMeasure":"events (deaths)"}